ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AbbVie bags option on Turnstone oncolytic virus candidates
fiercebiotech
October 11, 2017AbbVie has secured an option on three of Turnstone Biologics’ oncolytic viral immunotherapies. The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
Pharma Sources Insight January 2025
